Orphanet Journal of Rare Diseases
An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive review
Orphanet Journal of Rare Diseases201712:130
DOI: 10.1186/s13023-017-0681-6
© The Author(s). 2017
Received: 7 February 2017
Accepted: 7 July 2017
Published: 17 July 2017
Abstract
ᅟ
Behçet’s disease (BD) is a systemic vasculitis characterised by a relapsing remitting course, affecting multiple organ systems. In the eye, it is a cause of potentially blinding inflammation in the form of uveitis. Management of uveitis in BD often requires the use of systemic immunosuppression, in order to reduce disease activity and prevent accumulation of irreversible damage. Whilst corticosteroids remain the mainstay of treatment, long-term use is limited by the development of adrenocorticotrophic side effects. There has therefore been significant interest in the use of corticosteroid-sparing immunosuppressive agents, and more recently, biologic therapies. Recent publications have demonstrated biologic therapy to have beneficial effects both on overall disease control, and quality of life for patients with BD. Widespread use of such agents is however limited, partly by the lack of high quality research evidence, and partly by the prohibitive cost of biologic treatments. In this review, we discuss the most recent research investigating the use of biologic therapy in uveitis due to BD, with consideration of health economics and quality of life outcomes.
No hay comentarios:
Publicar un comentario